We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
CheckMate 141: 1‐Year Update and Subgroup Analysis of Nivolumab as First‐Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer.
- Authors
Gillison, Maura L.; Blumenschein Jr., George; Fayette, Jerome; Guigay, Joel; Colevas, A. Dimitrios; Licitra, Lisa; Harrington, Kevin J.; Kasper, Stefan; Vokes, Everett E.; Even, Caroline; Worden, Francis; Saba, Nabil F.; Iglesias Docampo, Lara Carmen; Haddad, Robert; Rordorf, Tamara; Kiyota, Naomi; Tahara, Makoto; Monga, Manish; Lynch, Mark; Li, Li
- Abstract
Abstract: Nivolumab significantly improved overall survival (OS) vs investigator's choice (IC) of chemotherapy at the primary analysis of randomized, open‐label, phase 3 CheckMate 141 in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). Here, we report that OS benefit with nivolumab was maintained at a minimum follow‐up of 11.4 months. Further, OS benefit with nivolumab vs IC was also noted among patients who received first‐line treatment for R/M SCCHN after progressing on platinum therapy for locally advanced disease in the adjuvant or primary (i.e., with radiation) setting.
- Subjects
THERAPEUTIC use of monoclonal antibodies; PLATINUM compounds; CANCER relapse; HEAD tumors; METASTASIS; NECK tumors; SURVIVAL; RANDOMIZED controlled trials; TREATMENT effectiveness; DISEASE progression; PROGNOSIS; THERAPEUTICS
- Publication
Oncologist, 2018, Vol 23, Issue 9, p1079
- ISSN
1083-7159
- Publication type
Article
- DOI
10.1634/theoncologist.2017-0674